FOLH1 and cancer: Upon the administration of iodine I 131 MIP-1095, the MIP-1095 moiety selectively targets and binds to the extracellular domain of PSMA, thereby delivering cytotoxic iodine I 131 specifically to PSMA-expressing cancer cells (35).”Antibodies and small particles differ in their molecular structure and function and exhibit differences in kinetics and biodistribution.